This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?

What's going on with CRISPR Therapeutics (NASDAQ: CRSP)? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn't recovered: The stock is down 23% year to date.Can CRISPR Therapeutics bounce back? Some recent developments could move the needle for the gene-editing specialist down the road. Let's find out what they are and what they mean for investors.Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. The list includes the U.S., the U.K., the European Union, Saudi Arabia, and Bahrain.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool